20-40% of patients with non small cell lung cancer (NSCLC) can develop brain metastases. Physiological activity on 18 F-FDG PET-CT can mask FDG-avid brain metastases. At our institution PET-CT is acquired from orbits to thighs and will not identify brain metastases extrinsic to the posterior fossa. Inaccurate staging could initiate futile radical treatment.
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The British Thoracic Society recommends NSCLC patients, considered for radical treatment (particularly stage III), should have a CT or MRI brain.
Aim
We evaluated results of patients who underwent head imaging in those considered for radical treatment of NSCLC and effect on baseline 18 F-FDG PET-CT staging.
Method
Retrospective study. 200 NSCLC cases from 2010 to 2015 that underwent PET-CT for potentially curative disease, were reviewed.
Results
17% (34/200) patients had head imaging. There was an average interval of 115 days between head imaging and PET-CT, ranging from 1 day to up to 2 years. 67% (23/34) patients received head imaging due to presenting neurological symptoms. 32% (15/49) patients with Stage IIIA disease had a CT/MRI brain resulting in 27% (4/15) having their initial PET-CT staging increased.
7.5% (15/200) patients had brain metastases. 93% (14/15) of these patients had presenting neurological symptoms.
Conclusion
Occult brain metastases can cause under staging with 18 F-FDG PET-CT imaging. CT/MRI head imaging requires more vigorous implementation into routine staging of patients with potentially resectable NSCLC. 
